PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

JP Buteau; AJ Martin; L Emmett; A Iravani; S Sandhu; AM Joshua; RJ Francis; AY Zhang; AM Scott; ST Lee; AA Azad; MM McJannett; MR Stockler; SG Williams; ID Davis; MS Hofman; T Akhurst; R Alipour; P Banks; A Beaulieu; W Chua; N Dhiantravan; K Ford; C Gedye; JC Goh; A Guminski; A Hamid; MB Haskali; RJ Hicks; E Hsiao; ID Kirkwood; G Kong; EM Kwan; A Langford; N Lawrence; J Lewin; P Lin; W McDonald; K Moodie; DG Murphy; S Ng; DA Pattison; I Pokorski; S Ramdave; AS Ravi Kumar; AD Redfern; NK Rutherford; J Saghebi; L Spain; S Subramaniam; TH Tan; SP Thang; B Tran; R Wallace; A Weickhardt; S Yip

Journal article

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, RJ Francis, AY Zhang, AM Scott, ST Lee, AA Azad, MM McJannett, MR Stockler, SG Williams, ID Davis, MS Hofman, T Akhurst, R Alipour, P Banks, A Beaulieu Show all

Lancet Oncology | Published : 2022

DOI: 10.1016/S1470-2045(22)00605-2

Abstract

Background: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate and progression-free survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer. In this study, we aimed to analyse gallium-68 [68Ga]Ga-PSMA-11 PET (PSMA-PET) and 2-[18F]fluoro-2-deoxy-D-glucose PET (FDG-PET) imaging parameters as predictive and prognostic biomarkers in this patient population. Methods: TheraP was a multicentre, open-label, randomised phase 2 trial that recruited men with metastatic castration-resistant prostate cancer after treatment with docetaxel who were sui..

View full abstract

University of Melbourne Researchers

James Patrick Buteau Author

Shahneen Sandhu Author

Andrew Scott Author

Arun Azad Author

Grants

Awarded by U.S. Department of Defense

Funding Acknowledgements

TheraP is a partnership between the ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia with support from the Australian Nuclear Science and Technology Organization; Endocyte, a Novartis Company; Movember Foundation; The Distinguished Gentleman's Ride; It's a Bloke Thing; and CAN4CANCER. MSH is supported by grants from the Prostate Cancer Foundation funded by CANICA Oslo Norway, the Peter MacCallum Foundation, Medical Research Future Fund, an NHMRC investigator grant, Movember Foundation, the US Department of Defence, and the Prostate Cancer Foundation of Australia. JPB has PhD support through an Australian Government research training programme scholarship.